Literature DB >> 22228276

The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.

Łukasz Kuźbicki1, Dariusz Lange, Anita Strączyńska-Niemiec, Barbara W Chwirot.   

Abstract

Early cutaneous melanomas may present a substantial diagnostic challenge. We have already reported that expression of cyclooxygenase-2 (COX-2) may be useful for differentiating between cutaneous melanomas and naevi. The purpose of this study was to examine the value of COX-2 in a challenging task of differential diagnosis of early melanomas and melanocytic naevi considered by histopathologists as morphologically difficult to unequivocally diagnose as benign lesions. The material for the study comprised formalin-fixed paraffin-embedded samples of 46 naevi (including 27 cases of dysplastic, Spitz and Reed naevi) and 30 early human cutaneous melanomas. The expression of COX-2 was detected immunohistochemically. Melanomas expressed COX-2 significantly more strongly compared with naevi. The test, on the basis of determination of the percentage fractions of COX-2-positive cells, allows for differentiation of early skin melanomas and naevi with high sensitivity and specificity. Receiver operating characteristic analysis of the test results yielded areas under receiver operating characteristics curves (AUC)=0.946±0.030 for central regions and AUC=0.941±0.031 for the peripheries of the lesions. The performance of the test in differentiating between melanomas and the naevi group comprising dysplastic, Spitz and Reed naevi was also good, with AUC=0.933±0.034 and 0.923±0.037 for the central and the border regions of the lesions, respectively. Using a more complex diagnostic algorithm also accounting for the staining intensity did not result in an improvement in the resolving power of the assay. A diagnostic algorithm using differences in the percentage fractions of cells expressing COX-2 may serve as a useful tool in aiding the differential diagnosis of 'histopathologically difficult' benign melanocytic skin lesions and early melanomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228276     DOI: 10.1097/CMR.0b013e32834defec

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  8 in total

Review 1.  Melanoma Chemoprevention: Current Status and Future Prospects.

Authors:  Gagan Chhabra; Mary Ann Ndiaye; Liz Mariely Garcia-Peterson; Nihal Ahmad
Journal:  Photochem Photobiol       Date:  2017-04-27       Impact factor: 3.421

Review 2.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 3.  Aspirin and other NSAIDs as chemoprevention agents in melanoma.

Authors:  James R Goodman; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-02

4.  Aspirin in dermatology: Revisited.

Authors:  Aditya Kumar Bubna
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

5.  Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?

Authors:  Łukasz Kuźbicki; Dariusz Lange; Agata Stanek-Widera; Agnieszka Glińska; Barbara W Chwirot
Journal:  Oncotarget       Date:  2018-04-03

6.  The role of immunohistochemistry expression of COX-2 in differentiating pigmented benign and malignant skin neoplasms.

Authors:  Maryam Ghasemi; Parvaneh Afshar; Somayeh Sheidaei; Yosef Moeini; Lale Vahedi Larijani
Journal:  Med J Islam Repub Iran       Date:  2019-07-25

Review 7.  COX-2 as a potential biomarker and therapeutic target in melanoma.

Authors:  Diana Valentina Tudor; Ioana Bâldea; Mihai Lupu; Teodor Kacso; Eniko Kutasi; Andreea Hopârtean; Roland Stretea; Adriana Gabriela Filip
Journal:  Cancer Biol Med       Date:  2020-02-15       Impact factor: 4.248

8.  ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma.

Authors:  Amir Varedi; Hafeez Rahman; Dileep Kumar; Jonathan L Catrow; James E Cox; Tong Liu; Scott R Florell; Kenneth M Boucher; Nwanneka Okwundu; William J Burnett; Matthew W VanBrocklin; Douglas Grossman
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.